跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
TEVA-FLUTICASONE - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
TEVA-FLUTICASONE
Authorized
STANDARD
TEVA-FLUTICASONE
teva canada limited
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
aa04e03a3cfdfe21
Company
teva canada limited
Type
Standard
Approval Details
Approval Id
aa04e03a3cfdfe21
Drug Approval Canada Name
TEVA-FLUTICASONE
Product Name
TEVA-FLUTICASONE
Status
Marketed
Status Date
2017-09-28
Original Market Date
2017-09-28
Din
02453738
Drug Class
Human
Dosage Form
Metered-Dose Pump
Route Of Administration
Nasal
Schedule
Prescription
Ahfs
52:08.08
Atc Original
R01AD08 FLUTICASONE
Atc Name
r 01 ad 08
Aig Number
0124685001
Company Name
teva canada limited
Company Address
30 Novopharm Court, Toronto, Ontario, Canada, M1B 2K9
Active Ingredients
FLUTICASONE PROPIONATE
50 MCG / ACT
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
aa04e03a3cfdfe21
Type
Standard
Back to Health Canada Approvals